Recent developments
I chaired the Working Party which has tackled the revision, under the impression that this would be a straightforward task encompassing primarily the grading of evidence just mentioned and legislative changes that have imposed even greater stringency on how radioisotopes are used medically. It soon became clear, however, that, as well as the difficulties of finding the necessary proof to grade the evidence supporting existing recommendations, much had changed in the field. Perhaps the biggest development has been the increasing use of radioactive iodine for the treatment of goitre. 3 Until recently, the only two options for dealing with an unsightly or symptomatic goitre have been levothyroxine treatment, given in sufficient doses to suppress the thyroid stimulating hormone (TSH) (with consequent risks of osteopenia and atrial fibrillation) or surgery. Levothyroxine therapy has a success rate of only 30-60%, depending on goitre size, and non-toxic goitre recurs in 15-40% of patients after surgery. By contrast, radioiodine treatment in non-toxic goitre can achieve a reduction in the size of the thyroid of around 50%, and further reduction can occur with a second dose. Apart from hypothyroidism, complications appear minimal although the risks of any subsequent extrathyroidal malignancy remain unknown. Given the increasing enthusiasm for this treatment, particularly when used with recombinant TSH to increase radioiodine uptake and thus minimise radiation dosage, the Working Party felt that we should include this area within the guidelines, which have therefore been retitled to encompass the management of benign thyroid disease rather than hyperthyroidism alone.
Among other developments, the Working Party has considered the evidence that radioactive iodine may worsen thyroid-associated ophthalmopathy, particularly found in smokers, as well as strategies which can be used to minimise this complication. 5 Although still controversial, there are prospective controlled trial data to show an adverse effect of radioiodine on ophthalmopathy. On the other hand there are currently no controlled trial data on whether radioactive treatment is indicated in subclinical hyperthyroidism (that is, those patients who have a suppressed TSH but normal serum free The use of radioiodine in the management of benign thyroid disease Tony Weetman on behalf of the Working Party of the Royal College of Physicians triodothyronine (T3) and thyroxine (T4) concentrations), despite the frequency with which this condition is now being uncovered with the increased use of thyroid function tests in a general population. Recent North American guidelines have indicated that treatment should be considered in subclinical hyperthyroidism, particularly in those over the age of 60, in those who have heart disease or evidence of increased bone loss, or in those who have symptoms suggestive of thyrotoxicosis. 4 An important trial led by Simon Pearce in Newcastle upon Tyne is about to start which will examine this question in detail but until the results of this and other trials are available, the Working Party has had to make recommendations for radioiodine usage based on the meagre evidence available.
A further area of contention has been the effect of antithyroid drugs on the outcome after radioiodine. These drugs are often given with the hope of avoiding the rare complication of thyroid crisis (or storm) but this tends to be something done by local custom and practice. Nevertheless, we now have clear evidence that propylthiouracil in particular has a radioprotective action which can reduce the effectiveness of radioactive iodine, even if this drug is stopped several weeks before radioactive iodine is administered. On the other hand, carbimazole appears to have no radioprotective effect provided it is withdrawn shortly before radioactive iodine administration.
Of course, the new guidelines have covered the UK legislative requirements for the administration of radioactive iodine, and I am particularly grateful to the many bodies that have provided advice to ensure that these areas and others have been dealt with as accurately as possible. We have simplified the range of 131 I activities which might be prescribed for different thyroid conditions, and provided new information on the radiation protection issues which arise after the administration of radioiodine. Equally important is the information given to the patient after treatment, and we have made recommendations that this information should be accompanied by a portable card with details of treatment date and dose. This is necessary for six months after treatment in the case of travel, during which time sufficient radioactivity may be retained by the patient to trigger security alarms at airports and other facilities. 6 Since hyperthyroidism and non-toxic goitre are such common conditions, all physicians are likely to come into contact with patients who need, or have had, radioactive iodine. On behalf of the Working Party, I hope that the revised guidelines will be of use to them as well as to endocrinologists and nuclear medicine specialists who are directly involved in the administration of radioactive iodine.
